Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia

J Alzheimers Dis. 2019;69(1):83-90. doi: 10.3233/JAD-181088.

Abstract

Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.

Keywords: Biomarker candidate; NIA-AA research framework diagnostic criteria; soluble amyloid-β protein precursor β.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnosis*
  • Amyloid beta-Protein Precursor / blood*
  • Amyloid beta-Protein Precursor / cerebrospinal fluid
  • Biomarkers / blood
  • Biomarkers / cerebrospinal fluid
  • Dementia / blood
  • Dementia / diagnosis*
  • Female
  • Humans
  • Male
  • Middle Aged
  • tau Proteins / cerebrospinal fluid

Substances

  • Amyloid beta-Protein Precursor
  • Biomarkers
  • tau Proteins